UPDATE: Morgan Stanley Downgrades Alkermes Plc to Underweight, Names $61 PT as Good News is Appreciated

In a report published Thursday, Morgan Stanley analyst David Risinger downgraded the rating on Alkermes Plc ALKS from Equal-Weight to Underweight, but named a $61.00 price target. In the report, Morgan Stanley noted, "Downgrade from E-W to UW relative to our coverage universe on expectations for weak lauroxil launch plus risk of Ampyra going generic sooner than expected.Setting a PT of $61 (12x our '16E rev), a 20% premium to the comp median of 10x." Alkermes Plc closed on Wednesday at $67.12.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorDowngradesAnalyst RatingsDavid RisingerMorgan Stanley
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!